Kyodo Pharmaceutical (300966.SZ) announced first-half results, with a net loss of 32.8413 million yuan to mother

Zhitongcaijing · 1d ago

According to the Zhitong Finance App, Kyodo Pharmaceutical (300966.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved revenue of 346 million yuan, an increase of 14.51% over the previous year. The net loss attributable to shareholders of the listed company was RMB 32.8413 million, and the net loss attributable to shareholders of the listed company after deducting non-recurring profit and loss was RMB 32.6654 million.